Mylan has received a Department of Justice subpoena into its opioid business, according to a quarterly securities filing.

Two new lawsuits claim consumers aren’t reaping all of the benefits from low generic prices. Pharmacies and PBMs are winning instead, they say.

New Hampshire filed a lawsuit against Purdue Pharma for allegedly leading an information campaign to boost opioid perception among prescribers.

The feds are eyeing top pharmas for patient assistance funding—and with one settlement in the works, those players should be scrambling.

Martin Shkreli, who became notorious for jacking up the price of a drug by 5,000%, has been convicted in New York of federal securities fraud.

Gilead Sciences is said to be evaluating United Therapeutics, although it finds itself in competition with GlaxoSmithKline and perhaps others.

With an appeals ruling, Roche will have to head back to court to defend against Accutane liability cases.

With billions in sales under threat, AbbVie is going all out in defense of its key drug and the world’s best seller, Humira.

Daiichi Sankyo, already losing sales to generics of blockbuster Benicar, has agreed to pay $300 million to settle litigation tied to the drug.